Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12736607 | 1.00 | NAAA (0.38) | NAAAHTR1AHCRTR2ALDH1A1ACACB | |
| SCHEMBL14922552 | 0.95 | NAAA (0.40) | NAAAHTR1AHCRTR2ACACBKDM1A | |
| SCHEMBL14766900 | 0.93 | NAAA (0.39) | NAAAHTR1AHCRTR2ACACBKDM1A | |
| SCHEMBL14765825 | 0.93 | NAAA (0.39) | NAAAHTR1AHCRTR2ACACBKDM1A | |
| SCHEMBL15381759 | 0.91 | NAAA (0.38) | NAAAHTR1AHCRTR2ACACBKDM1A | |
| SCHEMBL10302578 | 0.91 | NAAA (0.38) | NAAAHTR1AHCRTR2ACACBKDM1A | |
| SCHEMBL15381649 | 0.91 | NAAA (0.38) | NAAAHTR1AHCRTR2ACACBKDM1A | |
| SCHEMBL12736610 | 0.91 | SCN9A (0.33) | NAAAHTR1A | |
| SCHEMBL12740212 | 0.91 | SCN9A (0.33) | NAAAHTR1A | |
| SCHEMBL10303231 | 0.90 | NAAA (0.38) | NAAAHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8394294-B2 | Four-ring liquid crystal compound having lateral fluorine, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2013-03-12 | — | — | US | disclosed |
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110090450-A1 | FOUR-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, EFHD2 | NAAA 3997/4885HTR1A 484/4885HCRTR2 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.